We’re celebrating big news from two CryoportSystems valued clients: bluebird bio and Bristol Myers-Squibbannounced FDA approval of their cell therapy Abecma, a personalized immune therapy for patients with multiple myeloma.
While the pandemic continues to disrupt many industries, including regenerative medicine, it’s not all bad news -- in fact, there are likely some bright spotsahead for the industry this year.
Cryoport® is a trademark of Cryoport, Inc. and used with permission by Cryoport Systems, LLC
Exciting News! Cryoport, Inc., our parent company, has expanded its family of companies in continuing to support temperature controlled supply chain solutions for the life sciences industry. Learn More
